EARS实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Jul 2021 @ 12:00):

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders...

Stats
今日成交量	174 066
平均成交量	1.89M
市值	4.21M
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	-2.05
ATR14	CHF0.243 (7.98%)

音量相关性

長: 0.48 (neutral)

短: 0.85 (strong)

Signal:(42.109) Same movement expected

Auris Medical Holding Ltd 相关性

10 最正相关
CVRX	0.883
LCFY	0.882
BBLG	0.873
TRVN	0.868
JACK	0.862
QIPT	0.861
WBA	0.861
BIIB	0.86
EDAP	0.86
LIQT	0.858

10 最负相关
IXAQ	-0.878
INZY	-0.869
OSW	-0.863
VOXX	-0.859
TXRH	-0.857
CPRT	-0.855
EYEN	-0.853
QYLG	-0.851
QQQ	-0.85
IRTC	-0.85

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Auris Medical Holding Ltd 相关性 - 货币/商品

-0.31
( neutral )

-0.26
( neutral )

0.00
( neutral )

-0.30
( neutral )

0.51
( weak )

0.19
( neutral )

Auris Medical Holding Ltd 财务报表

Annual	2023
营收:	CHF0
毛利润:	CHF0 (0.00 %)
EPS:	CHF-14.80

FY	2023
营收:	CHF0
毛利润:	CHF0 (0.00 %)
EPS:	CHF-14.80

FY	2022
营收:	CHF305 616
毛利润:	CHF-1.14M (-372.44 %)
EPS:	CHF-29.13

Financial Reports:

No articles found.

Auris Medical Holding Ltd

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.